The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/bjc2015233.pdf
Reference59 articles.
1. Andersen MH (2014) The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia 28 (9): 1784–1792.
2. Bain BJ, Ahmad S (2014) Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol 166 (6): 809–817.
3. Becker TM, Boyd SC, Mijatov B, Gowrishankar K, Snoyman S, Pupo GM, Scolyer RA, Mann GJ, Kefford RF, Zhang XD, Rizos H (2014) Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene 33 (9): 1158–1166.
4. Bendell JC, Hong DS, Burris HA 3rd, Naing A, Jones SF, Falchook G, Bricmont P, Elekes A, Rock EP, Kurzrock R (2014) Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol 74 (1): 125–130.
5. Birner P, Toumangelova-Uzeir K, Natchev S, Guentchev M (2010) STAT3 tyrosine phosphorylation influences survival in glioblastoma. J Neurooncol 100 (3): 339–343.
Cited by 500 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Therapeutic potential of anticancer activity of nitrogen-containing heterocyclic scaffolds as Janus kinase (JAK) inhibitor: Biological activity, selectivity, and structure–activity relationship;Bioorganic Chemistry;2024-11
2. The role of artificial intelligence in the development of anticancer therapeutics from natural polyphenols: Current advances and future prospects;Pharmacological Research;2024-10
3. Improving Skin Cancer Treatment by Dual Drug Co-Encapsulation into Liposomal Systems—An Integrated Approach towards Anticancer Synergism and Targeted Delivery;Pharmaceutics;2024-09-12
4. Targeted nanomedicine modulating intercellular communications to arrest renal cell carcinoma progression;Journal of Drug Delivery Science and Technology;2024-09
5. Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance;Cancers;2024-08-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3